文献速递白血病

成人急性淋巴细胞白血病诱导治疗中延迟给予培门冬酶与高级别肝毒性风险降低相关且不影响结局

Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.
PubMed 文献 · Br J Haematol · 2024-11-06

该回顾性研究纳入141例新诊断成人急性淋巴细胞白血病患者,比较诱导期第4天早期给予培门冬酶(EP组78例)与第15天延迟给予(DP组63例)的肝毒性及疗效。DP组高级别肝毒性风险较低(比值比=0.44;P=0.04),完全缓解率、微小残留病阴性率及生存均无显著差异。

要点

  • 延迟至第15天给予培门冬酶与高级别肝毒性风险降低相关(比值比=0.44;P=0.04)。
  • EP组与DP组完全缓解率及诱导后微小残留病阴性率无差异。
  • 两组总生存与无事件生存无显著差异。

核心结论

  • 成人急性淋巴细胞白血病诱导周期中将培门冬酶从第4天延迟至第15天给药可能降低高级别肝毒性风险而不对临床疗效结局产生不利影响。

研究设计与样本

  • 回顾性研究,纳入2013年11月至2024年2月期间接受诱导期培门冬酶的141例新诊断成人急性淋巴细胞白血病患者。
  • 早期培门冬酶(EP)组78例(55.3%)于第4天给药,延迟培门冬酶(DP)组63例(44.7%)于第15天给药。

主要发现

  • 高级别肝毒性(≥3级转氨酶升高和/或高胆红素血症)在EP组发生更频繁(P=0.06)。
  • EP组与DP组诱导后完全缓解率及微小残留病阴性率无差异。
  • 单因素逻辑回归分析显示体重指数和年龄显著预测高级别肝毒性风险增加,而DP与较低风险相关(比值比=0.44;P=0.04)。
  • EP组与DP组总生存和无事件生存无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pegaspargase is a key drug for the treatment of younger adults with acute lymphoblastic leukaemia (ALL). Pegaspargase-associated hepatotoxicity is most common during induction, and its incidence increases with age and body mass index (BMI). We hypothesized that the delayed administration of pegaspargase during induction is associated with lower risk of hepatotoxicity while retaining efficacy. We retrospectively reviewed 141 adult patients with newly diagnosed ALL who received pegaspargase during induction from November 2013 to February 2024. There were 78 (55.3%) patients who received early pegaspargase (EP) on day 4 and 63 (44.7%) patients who received delayed pegaspargase (DP) on day 15. High-grade hepatotoxicity (grade ≥ 3 transaminitis and/or hyperbilirubinaemia) occurred more frequently in the EP group (p = 0.06). Rates of complete remission and negative minimal residual disease post induction were not different between cohorts. Univariate logistic regression analysis showed that BMI and age significantly predicted an increased risk of high-grade hepatotoxicity while DP was associated with a lower risk (odds ratio = 0.44; p = 0.04). Overall survival and event-free survival were not significantly different between cohorts. Delaying pegaspargase administration from day 4 to day 15 during induction cycle in adults with ALL might reduce the risk of high-grade hepatotoxicity without adversely impacting clinical efficacy outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Tinajero J, Xu S, Ngo D, et al. Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes. Br J Haematol. 2024. PMID: 39505575. doi:10.1111/bjh.19880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。